UK markets close in 1 hour 29 minutes

GenSight Biologics S.A. (0RIM.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
2.26000.0000 (0.00%)
As of 08:30AM BST. Market open.
Full screen
Previous close2.2600
Open2.2600
Bid0.0000 x 0
Ask0.0000 x 0
Day's range2.2600 - 2.2600
52-week range2.2600 - 2.2600
Volume254
Avg. volumeN/A
Market cap64.298M
Beta (5Y monthly)2.82
PE ratio (TTM)N/A
EPS (TTM)-0.6330
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    GenSight Biologics Announces Participation and Presentation of GS010 Clinical Data at EUNOS 2022

    PARIS, June 16, 2022--Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma Company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that it will participate to the EUNOS 2022 meeting, which is taking place on June 20-23 in Birmingham, United Kingdom. The conference is the most important conference in Europe for neuro-oph

  • Business Wire

    GenSight Biologics Announces Publication of a Study of the Impact of LHON Disease on the Lives of Patients and Relatives in Journal of Neuro-Ophthalmology

    PARIS, May 19, 2022--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma Company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the highly-regarded Journal of Neuro-Ophthalmology has published a qualitative study to explore the impact of Leber Hereditary Optic Neuropathy (LHON) on patients and their relatives. The study was fe

  • Business Wire

    GenSight Biologics: Annual General Meeting on May 25, 2022

    PARIS, May 04, 2022--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that it will hold its Annual General Meeting on May 25, 2022, at 9:00 am CEST at the Company’s headquarters, 74 rue du Faubourg Saint-Antoine, 75012 Paris, France (*).